Kiniksa Pharmaceuticals International PLC (NASDAQ: KNSA) is a biopharmaceutical company focused on developing treatments for inflammatory and autoimmune diseases. The company is incorporated in the United Kingdom with its principal U.S. operations located in Lexington, Massachusetts. Kiniksa's pipeline, as disclosed in its 10-K filed February 24, 2026 for the fiscal year ended December 31, 2025, includes KPL-387, a product candidate in Phase 2 clinical development for recurrent pericarditis, and KPL-1161, for which the company plans to initiate a Phase 1 first-in-human trial by end of 2026. The company also disclosed plans to explore strategic alternatives for abiprubart. Kiniksa's shares trade on the Nasdaq Global Select Market in multiple share classes, including Class A, Class B, Class A1, and Class B1 ordinary shares.

Revenue model

The filing excerpts do not provide sufficient detail to characterize Kiniksa's revenue model for FY2025.

Products and services

Pipeline assets as of the 10-K filed February 24, 2026 include: KPL-387 (Phase 2, recurrent pericarditis, monthly subcutaneous self-administration formulation); KPL-1161 (pre-clinical, quarterly subcutaneous dosing planned); abiprubart (strategic alternatives being explored).

Customers and end markets

Target patient populations include individuals with recurrent pericarditis and other inflammatory or autoimmune conditions. Specific customer concentration or payor data are not disclosed in the filing excerpts.

Value-chain role

Clinical-stage drug developer. Kiniksa conducts clinical trials and development internally; commercialization and manufacturing details are not disclosed in the provided excerpts.

Geographic exposure

Incorporated in the United Kingdom; principal U.S. operations in Lexington, Massachusetts. Further geographic detail is not supported by the filing excerpts.

Source: SEC 10-K, filed 2026-02-24

Industry: Pharmaceutical Preparations Peers: Roivant Sciences Ltd